First human trial tests One-Shot gene fix for failing hearts
NCT ID NCT07137338
Summary
This is a very early study testing the safety of a single intravenous gene therapy for adults with a specific inherited form of heart muscle weakness (dilated cardiomyopathy). The therapy, called RP-A701, delivers a working copy of a faulty gene (BAG3) directly to the heart. Researchers will give the treatment to 8 high-risk patients to check for side effects and see if it might improve heart function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DILATED CARDIOMYOPATHY (DCM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Medical University of South Carolina
NOT_YET_RECRUITINGCharleston, South Carolina, 29425, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California, San Diego
RECRUITINGSan Diego, California, 92037, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.